RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage anti-immunoglobulin E (IgE) monoclonal antibody, RPT904, designed to treat various allergic conditions. The agreement grants RAPT global …